ALPS Advisors’s Gyre Therapeutics GYRE Stock Holding History

ALPS Advisors’s Portfolio GYRE Stock Details GYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-2,818	Closed	-$228K	–	900
2018 Q3	$228K	Buy	2,818 +517	+22%	+$41K	﹤0.01%	921
2018 Q2	$201K	Buy	+2,301	New	+$404K	﹤0.01%	917

Other funds holding GYRE

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

ALPS Advisors's GYRE Position: Q4 2018 in Review

ALPS Advisors sold out of Gyre Therapeutics (GYRE) in Q4 2018, closing a stake of 2,818 shares — an estimated $228K sold.

ALPS Advisors first reported a position in GYRE in Q2 2018 and held it in 2 quarters. The position peaked at $228K in Q3 2018. 65 funds tracked by Wall St. Rank hold GYRE as of Q4 2018.

ALPS Advisors reported no remaining Gyre Therapeutics position as of Q4 2018 after selling out during the quarter.
ALPS Advisors sold 2,818 Gyre Therapeutics shares in Q4 2018, an estimated $228K.
ALPS Advisors first reported a position in Gyre Therapeutics in Q2 2018 and held it in 2 quarters.
ALPS Advisors's Gyre Therapeutics position peaked at $228K in Q3 2018.
65 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q4 2018.

Based on ALPS Advisors's 13F filing for Q4 2018, filed 4 Feb 2019.